Chemist + Druggist is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


Chiesi halts production and UK supply of Vertab SR 240mg tablets

Manufacturer Chiesi has decided to discontinue Vertab® SR 240mg tablets in the UK, it announced yesterday (June 8).

The brand was discontinued on April 27 “due to challenges in the continuity of supply across the UK”, the pharmaceutical company said in a statement.

The remaining supplies will be sold throughout the year, the manufacturer added.

Chiesi said that its decision to cease production of its branded verapamil hydrochloride is “regrettable”, but it will allow the company to focus on “newer, more viable alternatives”.

Vertab® is a calcium channel blocker that can be used to treat high blood pressure and angina.

“Chiesi remains committed to delivering better care and quality of life for people living with hypertension and angina. The cardiovascular therapeutic area continues to be a primary focus in Chiesi’s research and development pipeline, and the production and commercialisation of innovative medicines remains its priority,” the manufacturer added.

A Department of Health and Social Care spokesperson told C+D today (June 9) that the government is aware of several suppliers of verapamil 240mg modified-release tablets.

“The government has well-established processes to deal with medicine shortages and discontinuations and we work closely with the Medicines and Healthcare products Regulatory Agency, NHS England and NHS Improvement and others to ensure risks to prevent any shortages and minimise risks when they do arise,” they added.

What do you make of this announcement?


Pharmacy Dispenser/ Technician
Bethnal Green North, London
Salary: Up to £30,000

Apply Now



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts